ArticleNature communications2026
In-situ revitalizing end-of-life MBR membranes via a curtain-type dynamic membrane process.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Membrane bioreactors (MBR), an industrial mainstay with over 15,000 installations worldwide, face severe sustainability challenges from frequent membrane replacement, generating over 500,000 tons of waste annually. Dynamic membranes, a promising alternative, are impeded in large-scale implementation by inherent issues of conventional flat-sheet designs, such as uneven flow distribution and performance instability. Herein, we propose a strategy that directly upcycles end-of-life hollow-fiber MBR membranes as substrates for curtain-type dynamic membranes (CTDMs). The curtain-type substrate layer rapidly forms a biofilm and attains stable effluent quality (turbidity <5 NTU) within 10 minutes. Exposing only 5% of the internal substrate surface for CTDM fabrication restores performance comparable to that of new MBR membranes while meeting discharge standards. Life-cycle assessment reveals a 1,070-fold reduction in carbon emissions (0.0025 vs. 2.67 kg CO
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.